Dynavax Technologies Co. (NASDAQ:DVAX) Shares Bought by Arizona State Retirement System

Arizona State Retirement System increased its holdings in Dynavax Technologies Co. (NASDAQ:DVAX – Get Rating) by 4.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 33,903 shares of the biopharmaceutical company’s stock after purchasing an additional 1,294 shares during the quarter. Arizona State Retirement System’s holdings in Dynavax Technologies were worth $361,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of DVAX. American Century Companies Inc. increased its stake in Dynavax Technologies by 4.7% during the 1st quarter. American Century Companies Inc. now owns 86,892 shares of the biopharmaceutical company’s stock worth $942,000 after buying an additional 3,902 shares in the last quarter. HighTower Advisors LLC purchased a new stake in Dynavax Technologies during the 1st quarter worth approximately $159,000. MetLife Investment Management LLC increased its stake in Dynavax Technologies by 57.4% during the 1st quarter. MetLife Investment Management LLC now owns 57,543 shares of the biopharmaceutical company’s stock worth $624,000 after buying an additional 20,984 shares in the last quarter. Allianz Asset Management GmbH grew its position in shares of Dynavax Technologies by 16.8% in the first quarter. Allianz Asset Management GmbH now owns 59,070 shares of the biopharmaceutical company’s stock valued at $640,000 after purchasing an additional 8,500 shares in the last quarter. Finally, Mackenzie Financial Corp grew its position in shares of Dynavax Technologies by 25.6% in the first quarter. Mackenzie Financial Corp now owns 16,190 shares of the biopharmaceutical company’s stock valued at $175,000 after purchasing an additional 3,300 shares in the last quarter. 94.26% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Stock Up 0.6 %

NASDAQ:DVAX opened at $11.03 on Monday. The company has a quick ratio of 8.44, a current ratio of 9.07 and a debt-to-equity ratio of 0.39. The stock’s fifty day moving average is $10.48 and its two-hundred day moving average is $11.07. Dynavax Technologies Co. has a 52 week low of $9.42 and a 52 week high of $17.48. The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of 7.07 and a beta of 1.48.

Dynavax Technologies (NASDAQ:DVAX – Get Rating) last announced its quarterly earnings data on Thursday, February 23rd. The biopharmaceutical company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.01). The company had revenue of $184.49 million during the quarter, compared to analyst estimates of $184.20 million. Dynavax Technologies had a net margin of 35.99% and a return on equity of 45.49%. Research analysts anticipate that Dynavax Technologies Co. will post -0.56 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on DVAX. StockNews.com began coverage on Dynavax Technologies in a research report on Thursday. They issued a “hold” rating for the company. HC Wainwright decreased their price target on Dynavax Technologies from $28.00 to $27.00 and set a “buy” rating on the stock in a research note on Friday, February 24th. Finally, JMP Securities decreased their price target on Dynavax Technologies from $25.00 to $24.00 in a research note on Wednesday, May 3rd. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

Insider Activity at Dynavax Technologies

In other Dynavax Technologies news, COO David F. Novack sold 17,515 shares of the firm’s stock in a transaction dated Thursday, May 4th. The stock was sold at an average price of $10.90, for a total transaction of $190,913.50. Following the transaction, the chief operating officer now owns 3,187 shares of the company’s stock, valued at $34,738.30. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, COO David F. Novack sold 17,515 shares of the firm’s stock in a transaction dated Thursday, May 4th. The stock was sold at an average price of $10.90, for a total transaction of $190,913.50. Following the transaction, the chief operating officer now owns 3,187 shares of the company’s stock, valued at $34,738.30. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Justin Burgess sold 22,371 shares of the firm’s stock in a transaction dated Monday, February 27th. The stock was sold at an average price of $10.38, for a total value of $232,210.98. The disclosure for this sale can be found here. 2.62% of the stock is currently owned by corporate insiders.

Dynavax Technologies Profile

(Get Rating)

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.